Overview of Research
Arroyo BioScience’s mission is to discover and develop drugs for diseases without good treatment options by targeting the Sphingosine-1-Phosphate (S1P) signaling pathway. The five receptor subtypes in the S1P family are implicated in multiple disease pathologies. They are a key component of the regulation of the vascular system, inflammation, angiogenesis and cancer. Arroyo BioScience’s initial focus is on projects with identified leads in inflammatory disease and fibrosis.
S1P receptor inhibitors have already proven their clinical effectiveness. Gilenya® (fingolimod), which binds to four of the five S1P receptors (but not S1PR2), was launched in the US by Novartis in October 2010 for the treatment of multiple sclerosis. Gilenya sales for the last 12 months were close to a billion dollars, despite the fact that the drug is not specific to any S1P receptor. Arroyo BioSciences is working to expand and develop its portfolio of highly selective S1P receptor-specific compounds in the most rapid, efficient and cost effective manner possible.
Arroyo BioSciences, LLC. has pursued the discovery of potent sphingosine 1-phosphate receptor 2 (S1PR2) antagonists since its inception, and believes that these have a unique therapeutic potential, because of its direct role in several pathways that lead to fibrosis. Of particular relevance is the finding that a S1PR2 antagonist has been reported to be effective in standard animal models of fibrosis of the liver and kidney.
We have discovered a family of potent and selective S1PR2 antagonists. Our lead compound has good pharmacokinetics, low toxicity, and has proved orally efficacious in a relevant disease model.